Project

Back to overview

Magnetically driven soft continuum robot-enabled localized prodrug delivery for cancer chemoimmunotherapy

English title Magnetically driven soft continuum robot-enabled localized prodrug delivery for cancer chemoimmunotherapy
Applicant Nelson Bradley
Number 206033
Funding scheme China 2016
Research institution Institut für Robotik und Intelligente Systeme ETH Zürich
Institution of higher education ETH Zurich - ETHZ
Main discipline Biomedical Engineering
Start/End 01.06.2022 - 31.05.2026
Approved amount 349'464.00
Show all

All Disciplines (2)

Discipline
Biomedical Engineering
Other disciplines of Engineering Sciences

Keywords (6)

Soft continuum robots; Prodrug; Targeted drug delivery; Localized drug delivery techniques; Microrobots; Magnetic catheters

Lay Summary (German)

Lead
Das Multi-Scale Robotics Lab der ETH Zürich und das Molecular Nanoassembly and Biomimetic Nanomedicine Lab der Shenyang Pharmaceutical University (SPU) haben sich zusammengetan, um ein medizinisches Verfahren zur Behandlung von schwer zugänglichen, bösartigen Tumoren durch die Kombination von Mikrorobotertechnologie mit einer fortschrittlichen Arzneimittelformulierung zu entwickeln.
Lay summary

Das Multi-Scale Robotics Lab der ETH Zürich und das Molecular Nanoassembly and Biomimetic Nanomedicine Lab der Shenyang Pharmaceutical University (SPU) haben sich zusammengetan, um ein medizinisches Verfahren zur Behandlung von schwer zugänglichen, bösartigen Tumoren durch die Kombination von Mikrorobotertechnologie mit einer fortschrittlichen Arzneimittelformulierung zu entwickeln. 

Dieses Verfahren soll am Beispiel des duktalen Adenokarzinoms der Bauchspeicheldrüse (PDAC) demonstriert werden. Extern erzeugte Magnetfelder werden ein magnetisches Roboterendoskop und einen Katheter steuern, um im Pankreasgang biologisch abbaubare, medikamentenfreisetzende Komponenten abzugeben. Das Verfahren wird einen wichtigen Fortschritt bei der lokalen Verabreichung von Medikamenten darstellen und kann für die Behandlung anderer Krebsarten oder anderer Krankheiten angepasst und genutzt werden.

Direct link to Lay Summary Last update: 22.12.2021

Lay Summary (English)

Lead
The Multi-Scale Robotics Lab at ETH Zurich and the Molecular Nanoassembly and Biomimetic Nanomedicine Lab at Shenyang Pharmaceutical University (SPU) have joined forces to develop a medical procedure for treating hard-to-reach malignant tumors by combining microrobot technology with an advanced drug formulation.
Lay summary

The Multi-Scale Robotics Lab at ETH Zurich and the Molecular Nanoassembly and Biomimetic Nanomedicine Lab at Shenyang Pharmaceutical University (SPU) have joined forces to develop a medical procedure for treating hard-to-reach malignant tumors by combining microrobot technology with an advanced drug formulation. Pancreatic ductal adenocarcinoma (PDAC) will be considered for demonstrating this procedure. Externally generated magnetic fields will steer a magnetic robotic endoscope and catheter to release biodegradable drug-eluting components into the pancreatic duct. The procedure will make important progress in localized drug delivery and can be adapted for treating other types of cancer or other diseases.

Direct link to Lay Summary Last update: 22.12.2021

Responsible applicant and co-applicants

Gesuchsteller/innen Ausland

Associated projects

Number Title Start Funding scheme
185039 Arbeitstitel "Soft Magnetic Robots: Modeling, Design and Control of Magnetically Guided Continuum Manipulators" 01.04.2019 Project funding

Abstract

Localized delivery can increase efficacy by concentrating therapeutic agents at pathological sites while simultaneously minimizing systemic side effects, which is particularly beneficial for cancer patients suffering from toxic chemotherapy. However, the development of local delivery technologies for efficient tumor treatment is impeded by a lack of appropriate delivery tools, proper drugs and dosing, and retention of drugs at the pathological sites. Aiming to address these challenges, the Multi-Scale Robotics Lab at the Swiss Federal Institute of Technology Zurich (ETH Zurich) and the Molecular Nanoassembly and Biomimetic Nanomedicine Lab at Shenyang Pharmaceutical University (SPU) will join forces to develop a minimally invasive procedure for treating hard-to-reach malignant tumors by combining a unique robotic targeted delivery technique based on magnetic soft continuum robots, cutting-edge drug release components, and advanced prodrug formulation. Pancreatic ductal adenocarcinoma (PDAC) has been chosen as a model for demonstrating the applicability of this procedure. Specifically, we will use externally generated magnetic fields to steer a soft robotic endoscope and catheter to deploy biodegradable drug-eluting components into the pancreatic duct. Upon degradation, the embedded nanomedicine will be gradually and sustainably released. The nanomedicine is composed of chemotherapeutic prodrugs and immunotherapeutic agents, which kills tumor cells and activates the immune system to fight tumors. After treatment, the drugs and components will be gradually degraded by the body, leaving nonharmful products that can be metabolized. The ultimate goal of the project will focus on establishing a complete delivery procedure for the treatment of this type of tumor, and analyzing the applicability of this combinatorial procedure by performing preliminary in vivo experiments. This approach will be extremely versatile, highly precise, long lasting, and minimally toxic. None of the current localized drug delivery methods can integrate all these advantages. With this minimally invasive procedure, we will provide options beyond palliative treatment for this type of cancer, ideally making the tumor regress to give patients the opportunity to have surgery or other treatments. Our procedure will realize significant progress in localized delivery technologies and can be adapted for treating other types of cancer or other diseases.
-